AUG 07, 2018 08:15 AM PDT

Is There a Best Time of Day to Administer Chemo?

A recent publication in the Journal of Pharmacological Sciences outlines how the efficacy of L-asparaginase is dose schedule dependent in breast-tumor bearing mice.

Asparagine is an amino acid involved in metabolic control of cell functionality in primarily nerve and brain tissue.  It is a common, non-essential amino acid synthesized by the body from oxaloacetate, which is an intermediate of the citric acid cycle in aerobic glycolysis (ATP producing pathway).  L-asparaginase is an enzyme that enhances the conversion of asparagine which is used by new cells for growth and energy for proliferation.  Without asparagine, DNA and RNA synthesis cease which results in programmed cell death.  Young, undifferentiated lymph cells (lymphoblasts) in particular are dependent on asparagine for energy.   L-asparaginase has been used for nearly a decade in patients with acute lymphoblastic leukemia (ALL) with significant success as a multi-drug chemotherapy treatment.  Researchers have been looking at its use for solid tumors in vitro but have not translated results to in vivo studies for tumor bearing patients. 

A group of Japanese researchers sought to further the understanding of L-asparaginase as a chemotherapy agent for solid tumors through investigation of its mechanism and potential efficacy dependence on changing physiological levels of asparagine in plasma.  In animals, asparagine levels in plasma vary; they are higher in the light phase of a day and much lower in the dark phase of a day. 

They specifically looked at breast-tumor cells and the anti-tumor effects of L-asparaginase in mice while varying the administration schedule to track effect.  The group maintained the mice in standardized light/dark cycle conditions to mimic days and nights.  Tumor cell growth in these mice was significantly inhibited by L-asparaginase when administered during the light cycle hours; conversely, when L-asparaginase was administered in the dark phase, there was no significant anti-tumor activity.  The evidence very clearly suggests differences in anti-tumor therapeutic efficacy of L-asparaginase in these tumorigenic mice based on when doses were given. 

It is not clear if dose schedule is considered for many chemotherapeutic agents in a clinical setting, nor if there is other research showing the value of investigating such concepts.  It is noteworthy to consider if a cancer driving mechanism has any circadian rhythm or regular pattern with potential to affect therapy outcomes.

Sources: Journal of Pharmacological Sciences, NIH PubChem, Polish Archives of Internal Medicine,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 05, 2018
Cancer
JUN 05, 2018
Precision vs. Personalized Medicine Part II: Personalized Approach
So often the phrases "Precision Medicine" and "Personalized Medicine" are used interchangeably. Are they really synonyms? Part II looks at Personalized Medicine...
JUL 17, 2018
Cancer
JUL 17, 2018
Experimental "Trojan Horse" Tumor Destruction Approach Using CRISPR
CRISPR can be used to dupe circulating tumor cells into killing their own main tumor after "re-homing" back with a death receptor for tumor destruction....
JUL 24, 2018
Cancer
JUL 24, 2018
Veterans with Cancer Get Streamlined Access to NCI Clinical Trials
Veterans with cancer, and the VA that cares for them, struggle to navigate the complex world of clinical trials but a collaborative agreement between VA and NCI could fix that....
AUG 14, 2018
Cancer
AUG 14, 2018
Can Zika Virus Help Neuroblastoma Patients?
Researchers in Florida published the potential for Zika virus to help in the treatment of Neuroblastoma in patients of all ages....
SEP 04, 2018
Cancer
SEP 04, 2018
Metal beads that could help reduce chemotherapy side effects in brain tumor
Brain tumors are one of the most challenging types of cancers to treat. Only 1 in 7 patients will survive the disease, and those survivors will usually suffer from lots of side effects becaus...
OCT 04, 2018
Videos
OCT 04, 2018
Zebrafish as Metastatic Cancer Model
Another Koch Institute Image Award winner from 2018 is presented in this video from MIT....
Loading Comments...